ArticleDiscover oncology2026
MMP3-based prognostic nomogram and risk stratification for vascular mimicry in oral squamous cell carcinoma progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) severely affects facial aesthetics and the quality of life of patients. Although clinicians continue to improve diagnostic and treatment methods, they still cannot effectively improve the survival rate. Previous studies have found that Matrix Metalloproteinases (MMP2 \MMP9) can promote the formation of vascular mimicry (VM) in tumor tissues, but the relationship between MMP3 and VM in tumors tissues has not been clarified. In this study, we investigated the relationship between MMP3 and VM in OSCC tissues. Lasso regression analysis identified VM formation as an independent risk factor for patient prognosis. Subsequent survival analysis revealed a significant difference in prognosis between the VM-positive group and the VM-negative group (P = 0.00054). The constructed nomogram demonstrated that higher MMP3 expression levels were associated with increased risk scores and decreased 1- and 3-year expected survival rates. ROC curve analysis indicated excellent predictive performance of the model, with 1-year AUC = 0.906 and 2-year AUC = 0.970. Decision curve analysis (DCA) further confirmed the clinical utility of the model. Collectively, these findings suggest that MMP3 is a negative prognostic biomarker in OSCC. Research into MMP3 as a therapeutic target could represent a new and valuable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.